Literature DB >> 23372112

Determinants of antiretroviral therapy initiation and treatment outcomes for people living with HIV in Vietnam.

Dam Anh Tran1, Anthony Shakeshaft, Anh Duc Ngo, Kylie-Ann Mallitt, David Wilson, Christopher Doran, Lei Zhang.   

Abstract

OBJECTIVES: This study explores patient characteristics that are significantly associated with very late combination antiretroviral therapy (cART) initiation (CD4 count ≤100 cells/mm³) and examines the association between patient characteristics and treatment outcomes, CD4 recovery, and mortality.
DESIGN: Data were obtained from the clinical records of 2,198 HIV/AIDS patients in 13 outpatient clinics across 6 provinces in Vietnam.
METHODS: Multivariate logistic regression and Cox proportional hazards regression were used to identify patient characteristics that are significantly associated with very late cART initiation and to measure relationships between patient characteristics and treatment outcomes.
RESULTS: Very late cART initiation was significantly associated with being male compared with female (odds ratio [OR], 0.36; 95% CI, 0.23-0.58), becoming HIV infected through injecting drugs (OR, 2.13; 95% CI, 1.09-4.14), and having opportunistic infections at cART initiation (OR, 1.69; 95% CI, 1.02-2.86). Being male (female vs male: hazard ratio [HR], 0.45; 95% CI, 0.20-0.98), very late cART initiation (timely vs late: HR, 0.18; 95% CI, 0.04-0.72), low baseline body mass index (BMI) (HR, 0.95; 95% CI, 0.92-0.98), and later baseline WHO clinical stage (WHO clinical stage IV vs combined group of stage I and II: HR, 5.70; 95% CI, 3.90-7.80) were significantly associated with death, whereas being female compared with male (HR, 1.51; 95% CI, 1.14-1.99) and timely cART initiation (HR, 35.45; 95% CI, 13.67-91.91) were significant predictors of CD4 recovery.
CONCLUSIONS: Timely testing of patients for HIV, increasing use of CD4 count testing services, and starting cART earlier are essential to reduce mortality and improve treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23372112     DOI: 10.1310/hct1401-21

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  5 in total

1.  Prevalence of Advanced HIV Disease, Cryptococcal Antigenemia, and Suboptimal Clinical Outcomes Among Those Enrolled in Care in Vietnam.

Authors:  Vu Quoc Dat; Sheryl Lyss; Nguyen Thi Hoai Dung; Le Manh Hung; Sherri L Pals; Ho Thi Van Anh; Nguyen Van Kinh; Moses Bateganya
Journal:  J Acquir Immune Defic Syndr       Date:  2021-12-15       Impact factor: 3.771

2.  Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS.

Authors:  Bach Xuan Tran; Long Thanh Nguyen; Cuong Duy Do; Quyen Le Nguyen; Rachel Marie Maher
Journal:  BMC Public Health       Date:  2014-01-10       Impact factor: 3.295

3.  Feasibility of dried blood spots for HIV viral load monitoring in decentralized area in North Vietnam in a test-and-treat era, the MOVIDA project.

Authors:  Tuan Anh Nguyen; Tram Hong Tran; Binh Thanh Nguyen; Tram Thi Phuong Pham; Nhung Thi Hong Le; Dung Viet Ta; Huong Thi Thu Phan; Long Hoang Nguyen; Mohand Ait-Ahmed; Hien Thi Ho; Fabien Taieb; Yoann Madec
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

4.  Trends in and determinants of loss to follow up and early mortality in a rapid expansion of the antiretroviral treatment program in Vietnam: findings from 13 outpatient clinics.

Authors:  Dam Anh Tran; Anh Duc Ngo; Anthony Shakeshaft; David P Wilson; Christopher Doran; Lei Zhang
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

5.  The Effect of a Multi-Level Intervention on the Initiation of Antiretroviral Therapy (ART) among HIV-Infected Men Who Inject Drugs and Were Diagnosed Late in Thai Nguyen, Vietnam.

Authors:  Carla E Zelaya; Nguyen Le Minh; Bryan Lau; Carl A Latkin; Tran Viet Ha; Vu Minh Quan; Thi Tran Mo; Teerada Sripaipan; Wendy W Davis; David D Celentano; Constantine Frangakis; Vivian F Go
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.